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Validity of leptin receptor-deficiency 
(db/db) type 2 diabetes mellitus 
mice as a model of secondary 
osteoporosis
Le Huang1, Yong-ke You2, Tracy Y Zhu3, Li-zhen Zheng1, Xiao-ru Huang2, Hai-yong Chen2, 
Dong Yao1, Hui-yao Lan2 & Ling Qin1,3
This study aimed to evaluate the validation of the leptin receptor-deficient mice model for secondary 
osteoporosis associated with type 2 diabetes mellitus (T2DM) at bone micro-architectural level. Thirty 
three 36-week old male mice were divided into four groups: normal control (db/m) (n = 7), leptin 
receptor-deficient T2DM (db/db) (n = 8), human C-reactive protein (CRP) transgenic normal control  
(crp/db/m) (n = 7), and human CRP transgenic T2DM (crp/db/db) (n = 11). Lumber vertebrae (L5) and 
bilateral lower limbs were scanned by micro-CT to analyze trabecular and cortical bone quality. Right 
femora were used for three-point bending to analyze the mechanical properties. Trabecular bone 
quality at L5 was better in db/db or crp/db/db group in terms of bone mineral density (BMD), bone 
volume fraction, connectivity density, trabecular number and separation (all p < 0.05). However the 
indices measured at proximal tibia showed comparable trabecular BMD and microarchitecture among 
the four groups. Femur length in crp/db/db group was significantly shorter than db/m group (p < 0.05) 
and cortices were thinner in db/db and crp/db/db groups (p > 0.05). Maximum loading and energy 
yield in mechanical test were similar among groups while the elastic modulus in db/db and crp/db/db 
significantly lower than db/m. The leptin-receptor mice is not a proper model for secondary osteoporosis 
associated with T2DM.
Type 2 diabetes mellitus (DM) is a major metabolic disorder that causes profound medical and socioeconomic 
burden. It currently affects about 382 million adults worldwide and it is projected to reach 592 million by 20301. 
Type 2 DM is associated with a series of complications that can affect multiple organ systems, including the bone. 
A recent meta-analysis of 12 studies shows that adults with type 2 DM are at a heightened risk of hip fracture 
with a relative risk of 1.72. Paradoxically, areal bone mineral density (BMD) measured by dual-energy X-ray 
absorptiometry (DXA) is found to be normal or higher in these patients3–5, leading to the hypothesis that type 
2 DM is associated with material and microstructural deficits of the bones which contribute to the increased 
fracture risk6,7.
The underlying mechanism for type 2 DM-induced osteoporosis is still elusive. It may involve excessive accu-
mulation of advance glycosylation end-products as a result of hyperglycemia, increased fat deposition at the bone 
marrow and impaired osteoblast function8–13. C-reactive protein (CRP) is an acute-phase reactant produced pri-
marily in the liver under the stimulation of pro-inflammatory cytokines such as interleukin-6 and tumor necrosis 
factor-α . Elevated CRP levels represent a state of low grade inflammation which has been shown to disturb bone 
metabolism and has been shown to be associated with enhanced risk of fragility fracture in the general popula-
tion14–17. A number of studies have described elevated CRP levels in patients with type 2 DM18–20. Whether bone 
fragility in type 2 DM is a result of elevated CRP levels is yet to be determined.
Leptin receptor-deficient (db/db) mouse was reported as an animal model of type 2 DM21. These animals had 
autosomal recessive mutation in the leptin receptor and had features typical of type 2 DM, including hyperphagic, 
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obese and hyperglycemia. The aim of this study was to evaluate bony statues at microarchitectural level to deter-
mine whether leptin receptor-deficient mice model was a potentially valid animal model for type 2 DM-associated 
secondary osteoporosis.
Materials and Methods
Groups. Thirty three 36-week old male mice purchased from Laboratory Animal Services Centre of the 
Chinese University of Hong Kong were used and grouped into 4 groups: normal control mice (db/m) (n = 7), 
leptin receptor knock-out type 2 DM mice (db/db) (n = 8), human CRP transgenic normal control mice 
(crp/db/m) (n = 7) and human CRP transgenic db/db type 2 DM mice (crp/db/db) (n = 11). All animals were 
sacrificed by injecting excessive pentobarbital after being anesthesia by ketamine solution at 36 weeks. Body 
weight of all the mice was recorded. Lumbar vertebrae 4 to 6 (L4–6) and bilateral lower limbs were harvested. 
Right femora were preserved in saline before three-point bending test while the rest of the samples were fixed 
with formalin and kept in 70% ethanol before use. The study was conducted with the approval from the Animal 
Experimentation Ethics Committee of the Chinese University of Hong Kong (AEEC No. 09/027/MIS) and was 
conducted according to the approved guideline.
Evaluation of bone architecture by micro-CT. For evaluation of trabecular bone density and microar-
chitecture, vertebral body L5 and a section of 850 μ m in length of proximal tibia below the growth plate were 
scanned with a micro-CT system (Micro CT 40, SCANCO Medical, Switzerland) at a voltage of 70 keV in a spatial 
resolution of 10 μ m for animal experimental studies. Measurements were repeated for each sample and the mean 
values were used for analysis. Volumetric BMD, ratio of bone volume and total volume (BV/TV), trabecular bone 
number (Tb.N), trabecular bone thickness (Tb.Th), trabecular bone separation (Tb.Sp) and structural model 
index (SMI) were collected and analyzed. SMI is an index for determining the plate- or rod-like geometry of 
trabecular structures. For an ideal plate and rod structure, the SMI value is 0 and 3, respectively. For a structure 
with both plates and rods of equal thickness the value lies between 0 and 3, depending on the volume ratio of 
rods and plates22. For evaluation of cortical bone architecture, a section of 900 μ m of the middle shaft of the right 
femur which comprised pure cortical bone was scanned with the same micro-CT system with settings as above. 
The following parameters were collected: the diameter of the cross-section area, thickness of the cortical bone.
Mechanical test. A material test machine (H25KS, Hounsfield Test Equipment Ltd.UK) with a 25N load 
cell was used for testing mechanical properties of the femur. The left femur was positioned horizontally with 
the anterior surface upwards and centered on the supports with 10 mm apart. Load was applied at the mid-shaft 
constantly with displacement rate of 5 mm/min and directed vertically to mid-shaft with anterior surface upward. 
After testing to failure, the force-displacement curves were recorded. Also the stress-strain curve was obtained 
by being normalized by stressed area. This conversion would be calculated automatically by the built-in soft-
ware QMAT (QMAT Professional; Tinius Olsen, Inc. Horsham, PA, USA). Failure force (N), elastic modulus 
(E-modulus = stress/strain), energy at yield (integration of the total area under the stress-strain curve) were 
obtained and analyzed by a built-in software QMAT based on our previous established protocols23.
Statistical analyses. All data were expressed as mean and standard deviation. Between-group differences 
were analyzed by one-way analysis of variance (ANOVA). All statistical analyses were performed by Statistical 
Package for the Social Sciences (SPSS, version 17.0, Chicago, IL, US). A p-value less than 0.05 was considered 
statistically significant.
Results
Leptin receptor knock-out type 2 DM leads to higher body weight. Human CRP transgene did 
not affect the body weight. Body weight was comparable between db/m and crp/db/m mice and between db/db 
and crp/db/db mice. Compared with db/m mice, db/db and crp/db/db mice had 58.5% and 70.7%, respectively, 
Figure 1. Body weight among the four groups of mice . Data are mean ± SD. ** p < 0.05 compared with db/m 
mice.
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significantly higher body weight (both p < 0.05). Compared with crp/db/m mice, body weight was also signifi-
cantly higher in db/db and crp/db/db mice (both p < 0.05) (Fig. 1).
Leptin receptor knock-out type 2 DM mice have higher trabecular bone density and better 
microarchitecture at L5. In general, indices of trabecular bone microarchitecture at L5 were comparable 
between db/m and crp/db/m mice, except that connectivity density was significantly higher in crp/db/m (Fig. 2). 
Compared to db/m mice, BMD, BV/TV, connectivity density, Tb.N and were all significantly higher and Tb.Sp 
significantly lower in db/db or crp/db/db mice (all p < 0.05) (Fig. 2). The largest difference was seen in connec-
tivity density, which was 5.6 times and 6.2 times higher for db/db and crp/db/db mice, respectively. Tb.Th did not 
differ among the four groups. The average SMI of db/db and crp/db/db mice was 1.202 and 0.889, respectively, 
which was lower than those of db/m (1.995) or crp/db/m (1.671) mice. This indicated that the trabeculae at L5 
contained more plate-like structure for db/db and crp/db/db mice while more rod-like structure for db/m and 
crp/db/m mice (Table 1). Indices of trabecular bone were comparable between db/db and crp/db/db mice. The 3D 
images of trabecular bone in L5 are shown in Fig. 3 where the images show particularly denser and better con-
nected trabeculae in db/db and crp/db/db mice compared with db/m and crp/db/m mice.
Comparable trabecular bone density and microarchitecture at the proximal tibia among 
groups. In contrast to the findings at L5, in general, indices of trabecular bone microarchitecture at the prox-
imal tibia did not differ significantly among the four groups of mice (Fig. 4). BMD was also found comparable 
among groups. There was a trend towards a lower BV/TV in db/db (mean: 0.086) and crp/db/db (0.077) mice 
compared with db/m (0.112) and crp/db/m (0.095) mice. Connectivity density tended to be lower in crp/db/m and 
crp/db/db. However, these differences did not reach statistical significance. Tb.N and Tb.Sp did not differ signifi-
cantly among groups. Tb.Th was similar between db/db and crp/db/db mice with average Tb.Th being 0.048 mm 
for both groups, respectively. Significant difference in Tb.Th was only found between db/m and crp/db/db mice. 
SMI at proximal tibia ranged from 2.08 to 2.48, with comparable SMI among groups, representing the trabecular 
bone at this region tended to contain more rod-like structure (Table 1). Figure 3 shows the 3D image of trabecular 
bone at the proximal tibia. The images show trabecular bone with similar density and connectivity among the 
four groups.
Figure 2. Trabecular bone quality parameters by micro-CT of the L5 vertebra in the four groups of 
mice. BMD: bone mineral density; Tb.N: trabecular number; Tb.Th: trabecular thickness; Tb.Sp: trabecular 
separation. Data are mean ± SD. ** p < 0.05 compared with db/m mice.
Groups L5 vertebra Proximal tibiae
db/m 2.00 ± 0.81 2.49 ± 0.84
crp/db/m 1.67 ± 0.61 2.08 ± 0.64
db/db 1.20 ± 1.16 2.41 ± 0.92
crp/db/db 0.89 ± 1.67 2.27 ± 0.52
Table 1. Structural Model Index (SMI) of the microarchitecture of trabecular bone at L5 vertebra and 
proximal tibia*. * SMI is an index for determining the plate- or rod-like geometry of trabecular structures. For 
an ideal plate and rod structure, the SMI value is 0 and 3, respectively. For a structure with both plates and rods 
of equal thickness the value lies between 0 and 3, depending on the volume ratio of rods and plates22.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:27745 | DOI: 10.1038/srep27745
Comparable cortical bone architecture at mid femoral shaft and mechanical properties among 
groups. The length of the femur was 8.55% (p < 0.05) significantly shorter in crp/db/db mice than in db/m 
mice (Fig. 5). Cross-sectional area and cortical thickness of the femur tended to be lower in db/db and crp/db/db 
group compared with db/m and crp/db/m mice but the differences were not statistically significant (p > 0.05). 
Group-wise differences in the maximum loading and energy yield were not significantly different (all p > 0.05) 
(Fig. 5). Compared with db/m mice, elastic modulus was 9.75% and 8.67% significantly lower (both p < 0.05) in 
db/db and crp/db/db mice, respectively.
Discussion
In this study, we investigated the bone density and microarchitecture at the spine and limb in a type 2 DM mice 
model. Leptin receptor knock-out type 2 DM led to significantly higher body weight and human CRP gene did 
not affect body weight as body weight was comparable between db/m and crp/db/m mice, and between db/db and 
crp/db/db mice. Assessment by micro-CT revealed high bone mass phenotype at L5 in type 2 DM mice (db/db) 
and type 2 DM mice with human CRP transgenic gene (crp/db/db), evidenced by significantly higher trabecular 
BMD, BV/TV, connectivity density, Tb.N and lower Tb.Sp. At the proximal tibia, Tb.Th was significantly lower in 
crp/db/db mice and there was a trend towards lower trabecular BV/TV in db/db and crp/db/db mice. Otherwise, 
Figure 3. 3D images of the trabecular bone by micro-CT of the L5 vertebra (upper row) and proximal tibia 
(bottom row) in the four groups of mice. 
Figure 4. Trabecular bone quality parameters by micro-CT of the proximal tibia in the four groups of 
mice. BMD: bone mineral density; Tb.N: trabecular number; Tb.Th: trabecular thickness; Tb.Sp: trabecular 
separation. Data are mean ± SD. ** p < 0.05 compared with db/m mice.
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cortical and trabecular bone density and microarchitecture at the proximal tibia was maintained in type 2 DM 
mice. Three-point bending test showed significantly lower elastic modulus and comparable loading and energy 
in type 2 DM mice.
Leptin receptor knock-out type 2 DM mice did not exhibit phenotype, on a bone microarchitectural level, typ-
ical of osteoporosis. Despite a large body of clinical and epidemiological studies linking type 2 DM to increased 
bone fragility and fracture risk, patients with type 2 DM are often found to have higher or normal BMD. Studies 
investigating bone microarchitecture in animal models of type 2 DM yield conflicting results24–30. The high bone 
mass phenotype at L5 in db/db mice found in our study is in consistent with the study by Ducy et al.24. They 
showed significantly higher trabecular BV/TV at L5 and femur in 6-month-old db/db mice. This high bone mass 
phenotype was found in both genders, despite coexisting hypogonadism and hypercortisolism and the appear-
ance of this phenotype preceded the onset of obesity24. Higher trabecular bone mass at the spine (L2–3) has also 
been reported in a leptin-deficient (ob/ob) mice model27.
In contrast, a number of studies have reported significantly lower bone mass and/or compromised trabecular 
microarchitecture in db/db25,28,30 or ob/ob mice model25,27, or obese Zucker ( fa/fa) rats model26,29, which is a type 2 
DM model with an inactivating mutation of the leptin receptor. However, the majority of this low bone mass phe-
notype was found at the limbs (femur or tibia)25–29 whilst the bone mass at the spine was reported to be normal25 
or higher27. In the study by Williams et al., although bone mass reduction was found at both the tibia and spine in 
db/db mice, the magnitude of the decrease was less in the spine evidenced by the finding that significant deterio-
ration of trabecular compartment at L5 was only found in Tb.Th30. Our findings are consistent with these previous 
results in that we found trends towards lower trabecular bone mass and Tb.Th at the tibia in db/db mice despite 
the high bone mass phenotype at the L5. Additionally, bone material property at the femur was also affected in 
db/db mice, evidenced by a lower elastic modulus. These findings suggest that leptin- or leptin receptor-deficiency 
produces differing bone phenotypes at the spine and limb. The greater loss of bone at the limb than at the spine 
could be due to the greater muscle loss at the limb as a result of obesity27. Bone remodeling is significantly affected 
by the muscle because muscle contraction produces the greatest load on bone31,32 and because muscle mass is the 
primary determinant of blood flow to the limb33,34. In ob/ob mice, the low bone mass at the femur was associated 
with the relatively low hind limb muscle mass. In addition, Hamrick et al. proposed that the difference in bone 
phenotype between the femur and lumbar spine of ob/ob mice could be partly explained by the differing response 
of marrow cells at these two skeletal sites to leptin deficiency27. Leptin deficiency and obesity are known to be 
associated with increased bone marrow adipogenesis which has been link to bone loss35,36. Marked adiposity in 
the femur suggesting excessive bone marrow adipogenesis, along with an absence of increased adipocyte number 
in the lumbar vertebrae, has been reported in ob/ob mice27.
CRP is a measure of chronic inflammation and is an independent risk factor for type 2 DM and cardiovascular 
disease37. Elevated CRP level can also interact with other risk factors to accelerate the progression of type 2 DM 
and its related complications, particularly cardiovascular diseases37,38. Previous studies have also found significant 
correlation between elevated CRP level and increased risk of fracture in general population and this correlation 
is independent of areal BMD measured by DXA14–17. In this study, we included groups of human CRP transgenic 
mice to investigate the role of CRP in the development of osteoporosis in type 2 DM. Although crp/db/db mice 
had shorter femur length than db/db mice, overall, crp/db/db mice did not exhibit poorer bone density and archi-
tecture than db/db mice. These findings do not support that CRP plays a detrimental role in deteriorating bone 
density and architecture in type 2 DM. However, our study did not examine degree of mineralization or potential 
micro-damage to bone matrix or properties of non-mineral phase of the bone, on which CRP might have a direct 
or indirect effect. The exact mechanism how CRP disturb bone metabolism and induces bone fragility in general 
population or in type 2 DM requires further studies.
Figure 5. Length, cortical area and thickness, and mechanical properties of the femur among the four 
groups of mice. E-modulus: elastic modulus. Data are mean ± SD. **p < 0.05 compared with db/m mice.
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There are some limitations of this study. First, due to the difficulty of measuring the femoral neck of mice, we 
performed the micro-CT scanning on the L5 and the proximal tibia instead. Our results may not be applicable to 
the femur which is a major site for fracture in type 2 DM. Second, we did not perform assessments on bone turno-
ver markers by blood sample or bone histomorphometry. The underlying alteration in the balance of bone metab-
olism responsible for the observed bone phenotype in this animal model was not studied. Finally, assessment of 
bone quality was conducted only at bone microarchitectural level. Some features of bone microarchitecture such 
as cortical porosity, micro-crack of one matrix or properties of non-mineral phase of the bone were not be able 
examined due to limitation of the assessment technology used for the current study. However, mechanical test 
was conducted to assess the whole bone strength and the results did not show significantly reduced bone strength 
in db/db mice.
Due to above mentioned study limitations, further studies are recommended. First of all since this study 
aimed to validate the secondary osteoporotic animal model, the mechanistic studies on how leptin receptor 
knock-out would induce increase of body weight would be subject to explore. Since we all know that leptin plays 
an important role in not only the contribution of type 2 DM but also bone metabolism, how this mutation would 
affect the bone quality would also be of our interests apart from weight bearing that is a known factor preventing 
bone loss. Moreover, as mentioned in results, the mineral phase of bone was not affected by the elevation of CRP 
the non-mineral phrase should be analyzed to understand the role of CRP on the bone structure.
In conclusion, the leptin receptor-deficient (db/db) mice did not exhibit significant compromised bone quality 
at microarchitectural level. However, deficiency in leptin signaling had differing effect on the spine and limb with 
high bone mass phenotype being particularly noticeable at the spine. There were trends towards lower trabecular 
bone mass and compromised microarchitecture at the tibia in the db/db mice. Overall, this mouse model does not 
exhibit phenotype typical of secondary osteoporosis. Human CRP transgenic db/db mice did not exhibit poorer 
bone mass and microarchitecture than db/db mice, suggesting that CRP does not play a detrimental role in dete-
riorating bone density and architecture in type 2 DM.
Ethics Approval. The study was cond.ucted with the approval from the Animal Experimentation Ethics 
Committee of the Chinese University of Hong Kong (AEEC No. 09/027/MIS).
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